Iterative Health Site Network
Performance-driven global clinical trial site network for GI, Hepatology, Obesity, and Cardiology research
Platform · HybridCompany source
Company profile
About Iterative Health
Iterative Health is a clinical research organization that operates a performance-driven global site network focused on accelerating clinical trials in Gastrointestinal, Hepatology, Obesity, and Cardiology therapeutic areas. The company brings research directly into community care settings, connecting pharmaceutical sponsors' scientific ambitions with empowered, high-performing research sites. Iterative Health partners with leading provider networks including GI Alliance, One GI, and US Heart & Vascular (USHV) to expand access to clinical trials across community-based practices. The company's mission centers on accelerating time to market for life-changing therapies while expanding patient access. Iterative Health provides comprehensive site enablement services including centralized contracting, regulatory support, quality assurance, and AI-powered patient recruitment tools. Their proprietary SKOUT® technology offers real-time AI-powered polyp detection for colonoscopy procedures, improving diagnostic quality in gastroenterology care. Iterative Health serves both clinical trial sponsors/CROs seeking faster, more predictable trial execution, and healthcare providers looking to grow their research capabilities. The company's network delivers industry-leading performance metrics including 2X faster clinical trial activation, 2X speed to first patient screened, and over 3X patient enrollment rates compared to industry benchmarks. With a patient reach exceeding millions and a growing network of research sites, Iterative Health is positioned as a strategic partner for advancing clinical research in its focused therapeutic areas.
Company description Iterative Health official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Iterative Health?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- ALD
- Autoimmune Hepatitis
- Barrett's Esophagus
- C.Diff
- Cardiac Electrophysiology
- Cardiovascular Outcomes
- Celiac
- EoE
- Gastroparesis
- GERD
- GI Oncology
- Heart Failure
- Hypertension
- IBD
- IBS-C/D/M/U
- MAFLD
- MASLD/MASH
- Obesity
- PBC
- Peripheral Vascular Disease
- PSC
- Structural Heart Disease
Who it serves
- Academic Medical Centers
- Ambulatory Surgery Centers
- Community-based GI practices
- CROs
- Health Systems
- Pharmaceutical Sponsors
Deployment & integration
Embedded · Hybrid deployment with recorded integration context.
Geographic context
MarketsGlobal · United States
Company sourceOfficial website
Company milestones
Platform expansion
Closed $77 Million Series C funding (April 2026), Acquired Cardiology Sites from NextStage Clinical Research (May 2026), Reported Expanded Trial Performance Data at Digestive Disease Week 2026 demonstrating consistent outperformance at double the scale (May 2026)
Partnerships
Recorded partners
- Gastro One
- GI Alliance
- One GI
- US Heart & Vascular (USHV)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
SKOUT
Real-time AI for polyp detection during colonoscopy procedures
Software · EmbeddedCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Neoplastic findings after positive multi-target stool DNA testing in a large gastroenterology practice.Current medical research and opinion · Aug 18, 2026
Artificial intelligence assessment of endoscopic severity and extent: A machine learning approach to continuous evaluation of endoscopic inflammation in ulcerative colitis.Inflammatory bowel diseases · Jul 17, 2026
Editorial for "Reliability of 4D Flow MRI-Derived Pulmonary Regurgitant Fraction in Repaired Tetralogy of Fallot: Impact of Measurement Location and Pulmonary Artery Geometry".Journal of magnetic resonance imaging : JMRI · Feb 1, 2026
Accuracy of calcified plaque volumes by AI-QCT coronary CT angiography: phantom and non-contrast CT verification.European heart journal. Imaging methods and practice · Jan 1, 2026
Machine Learning Models for the Assessment of the Mayo Endoscopic Score in Ulcerative Colitis Trial Endpoints: A Systematic Review.Inflammatory bowel diseases · Jan 1, 2026
Comparative evaluation of a hybrid machine learning-human adjudication paradigm for endoscopic scoring in ulcerative colitis.BMJ open gastroenterology · Dec 7, 2025
Clinical validation
Clinical-trial records
Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee OsteoarthritisNCT06216028 · Mentioned · NOT YET RECRUITING
Regulatory
Regulatory records
SKOUT systemK253664 · 510k · Dec 22, 2025
SKOUT systemK251126 · 510k · May 9, 2025
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
2X faster clinical trial activation
Compared to industry benchmarks
2X speed to 1st patient screened
Compared to industry benchmarks
3X patient enrollment rate
Compared to industry benchmarks
1 additional adenoma detected per 4.5 patients
High-performing endoscopists using SKOUT®
No increase in procedure time
SKOUT® polyp detection
Over 10% decline in polyp detection rates prevented
Standard colonoscopy from morning to afternoon
Tyler Research Institute (TRI)
Accelerated IBD Phase 2 trial activation and patient screening in community-based setting
Screened 6 patients in first 2 weeks post-activation vs industry benchmark of >75 days; randomized over 100 patients across dozen IBD Phase 2-3 trials with <15% screen fail rates
Gastro One
Accelerated a complex Phase 1b-A GI trial through streamlined operations, improved patient retention, and increased randomizations
Faster enrollment and measurable trial efficiency through targeted, high-touch support including proactive chart reviews and regulatory guidance
High-performing endoscopists using SKOUT
AI-assisted polyp detection during colonoscopy to improve adenoma detection rates
Resected 1 additional adenoma for every 4.5 patients examined with SKOUT, without increasing resection of hyperplastic polyps
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
G. Aaron DuVall
Founder and Principal Investigator
06 · Company updates
Updates from Iterative Health
Recent articles published on Iterative Health's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.